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ABSTRACT
Control of infection classically involves hand and healthcare hygiene, reduction of selective and
ineffective chemotherapy, reduction of invasive procedures and achlorhydria and adequate stafﬁng,
along with appropriate containment and concentration of patients. Investigation and control of any
continuing sources of infection in food and water supplies is important also, as is recognition of
individuals carrying high-risk strains and species. The onset of infection may be distant from the time of
acquisition and may critically affect epidemiological assessment of control points. Carriage may be
prolonged, increasing the likelihood of recurrent infection and exacerbating the difﬁculty of control.
Mortality associated with resistance is difﬁcult to assess retrospectively and may not be high,
complicating analysis of the success or failure of control measures.
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INTRODUCTION
Organisms producing extended-spectrum b-lac-
tamases (ESBLs) that developed as variants of the
TEM-1, TEM-2 and SHV-1 enzymes have caused
many local and national outbreaks, mostly within
specialised hospital units. Control has been difﬁ-
cult in proportion to the size of the outbreak, with
treatment for severe infections usually requiring
carbapenems. The recent, widespread emergence
of multiresistant strains of Escherichia coli with
CTX-M ESBLs and various pathogenicity factors
has further complicated control and creates an
acute and important international issue.[1] Resis-
tance in E. coli is important because the organism
is the commonest Gram-negative pathogen, is
widespread among populations, and is important
in healthcare settings other than hospitals.
Although resistances vary by country and strain,
many of the E. coli strains with CTX-M ESBLs are
also resistant to b-lactam–inhibitor combinations,
quinolones, trimethoprim, tetracycline, aminogly-
cosides and chloramphenicol, leaving few options
for treatment, apart from carbapenems, cepham-
ycins, fosfomycin (which is not marketed in the
UK), colistin, nitrofurantoin and, possibly, tige-
cycline.
SMALL AND LARGE OUTBREAKS OF
ESBL-PRODUCING ORGANISMS
Small hospital outbreaks of organisms producing
TEM and SHV ESBLs are frequent, and are often
due to single clones [2]. Transmission of ESBL (or
even AMPC or carbapenemase)-encoding plas-
mids within, and between, species may also occur
[3,4]. These small outbreaks are often centred on
particular environments such as intensive care
units [5], haemato-oncology units [6], urology
units [7], units for care of the elderly, wards for
long-stay gastrointestinal surgical patients, trans-
plantation units and neonatal units. The site of
infection relates to the particular environment
and the type of patient (with, e.g., ventilator-
associated pneumonia in intensive care unit
patients, or bacteraemia of gut origin in neutrope-
nic patients). Prior to theCTX-Mera, termination of
outbreaks due to resistant bacteria often involved
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the adoption of a hitherto unused antibiotic class.
Historical examples can be found at the times of
the successive introductions of trimethoprim,
cephalosporins or quinolones. These agents are
potent in modifying the gut ﬂora, reducing
carriage of epidemic resistance. Multiresistance,
and the fact that no new anti-Gram-negative
antibiotic classes are available, complicate the
control of CTX-M-producing strains.
PRINCIPLES OF CONTROL
Classic principles for controlling multiresistant
Gram-negative strains include reducing selection
pressure by avoiding all agents to which the
strain or plasmid donor organisms are resistant in
the carriage site, which is principally the gut in
the case of E. coli [8]. Gut carriage of resistant
E. coli strains has long been recognised as a risk-
factor for resistant urinary tract infection (UTI),
although these vary in virulence [9]. For ESBL
producers, not only cephalosporins [10] but also
other antibiotics [5] must be considered as selec-
tors. The gut concentration of active antibiotic is
important here (and for selection of Clostridium
difﬁcile) and may be high if there is residual
unabsorbed drug from oral agents or biliary
excretion combined with potency insufﬁcient to
be overcome by gut dilution. By contrast, drugs
active against ESBL producers may reduce the
chance of carriage [11]. The susceptibility of some
ESBL producers to parenteral aminoglycosides is
important, as these now infrequently used agents
seldom reach selective gut concentrations and so
may diminish selective pressures. More generally,
when considering which non-selective agents to
use, it should be noted that collateral damage is
not conﬁned to Gram-negative species in the gut
but extends to Gram-positive species at other
body sites [12]. For example, selection of methi-
cillin-resistant Staphylococcus aureus and entero-
cocci is associated with use of quinolones and
cephalosporins.
Classic control also emphasises minimising the
frequency of procedures that carry a risk of
promoting infection from colonisation. Urinary
catheterisation [13], endotracheal or nasogastric
intubations, gut surgery and induction of achlor-
hydria all increase the risk of infection by trans-
ferring Gram-negative organisms from
colonisation to infection sites. Antibiotic prophy-
laxis for invasive procedures in those colonised
with ESBL producer organisms should be tailored
against the colonising strain.
Ensuring adequate hand hygiene and staff ⁄
patient ratios minimises the risk of inter-patient
spread of resistant strains. Admission from other
hospitals or from residential care should generate
automatic alerts to detect readmitted patients
previously found to carry multiresistant ESBL
producers. Staff in the transferring units should
notify the receiving infection control staff of such
transfers. Single-room accommodation, or cohort
isolation, for both current and past cases, may
improve care and diminish the chances of spread.
Cohort wards are inﬂexible because of their ﬁxed
bed complement and the irreducible minimum of
staff required. Minimising the length of stay of
patients carrying an outbreak strain by early
discharge also reduces the chances of such
patients acting as sources of cross-infection or
cross-colonisation.
UK EXPERIENCE IN CONTROLLING
SPREAD OF E . COLI WITH CTX-M
ESBLS
The UK is affected by both diverse and clonally
related E. coli strains with CTX-M-15 (and rarely
other) ESBLs [14]. Infections due to these ESBLs
often become manifest in the community, where
there are no licensed oral agents suitable for use
if they cause an upper UTI. Older patients, not
the population with cystitis, are particularly
involved. The problem was recognised in two
Shropshire hospitals and their associated pri-
mary-care communities in April 2003, but retro-
spectively was identiﬁed as having started in
January, with earlier cases in the West Midland
region dating back to 2002 [15]. The problem
involved four of ﬁve related serotype O:25 clade
B2 strains with CTX-M-15 ESBLs, that were simul-
taneously appearing elsewhere in the UK, e.g.
Belfast (http://www.cdscni.org.uk/publications/
MonthlyReports/Volume_13_2004/DecNo10.pdf)
and Southampton (http://www.erpho.org.uk/
Download/Public/15092/1/cmoreport2005.pdf.
73). Outbreaks in these places had an identical time
course. This suggested a common-source outbreak,
although no source was identiﬁed, and analysis is
complicated because the O25 gene can be trans-
ferred among strains [16], and also because the
different clone occurred in different proportions
at different sites, with A, B, D and E in Shropshire,
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but A alone in Southampton, and A and C in
Belfast. A further complication is that not all
hospitals were ideally identifying ESBL producers,
or even identifying urinary isolates to species level.
This oligoclonal problem was not universal, as
CTX-M-15-producing E. coli emerged to become a
problem in the UK in 2003, and diverse CTX-M-
15-producing strains were detected simulta-
neously, without obvious clonality in other parts
of the country [17].
It is notable that E. coli strains with CTX-M
enzymes were clonal in Canada [18], France
[19,20] and Israel [21], but not in Spain [22] or
Italy [23], and, in some settings, plasmid spread
among E. coli strains, or recombination of ele-
ments from the plasmids, may be critical in the
rapid appearance of CTX-M-15-producing strains,
more so than the slower person-to-person spread
of clones, gradually emerging above detection
limits. However, this is speculative, and the
plasmids or transposable elements present in the
heterogeneous CTX-M-15-positive UK strains [17]
remain unknown.
All these differences in behaviour, clonality and
plasmid transmissibility are likely to affect re-
sponses to control measures, and may vary in the
UK context between different components of the
O25 clone and unrelated strains that are further
modulated by differences in their virulence fac-
tors [24] and antibiotic resistance proﬁles. Overall,
the present diversity and dynamics of strains and
self-transmissible plasmids imply that the prob-
lem can only be controlled, not eliminated.
Descriptive epidemiology and control
In the period 2003–2006 in Shropshire, 86% of a
total of 627 infections due to E. coli strains with
CTX-M-15 ESBLs involved the urinary tract,
comprising, overall, 3.5% of hospital and 1.6%
of community UTIs and, respectively, 8.5% and
3.6% of second and subsequent UTIs. Forty-seven
per cent were diagnosed in primary care settings
but only 20% had no history of admission to local
hospitals or residential care homes.
Descriptive epidemiology was applied to assess
potential sources and control points for ESBL
E. coli. Aside from contact with hospitals, these
early surveys suggested catheterisation and anti-
biotic use as controllable risk-factors. Sixteen pa-
tients with infections with gentamicin-susceptible
strains (dominantly Group A) were interviewed
during October–December 2003: 87%were female
(mean age 72 years); 50% had been catheterised
in the last 3 years; and 94% had been hospital
outpatients or inpatients in the preceding 3 years.
Prior antibiotic use had not been heavy: 75% had
received an antibiotic in the last 3 years but, on
average, each patient had only received a single
course each year. Diet, routine food purchase,
drinking from private water supplies and animal
contact did not suggest a source.
A further survey, through general practitioners,
of 73 contactable patients was conducted during
April–June 2004. Of these patients, 64% had been
in hospital, 18% were in residential healthcare
outside hospital, and 63% had been treated with
antibiotics in the 3-year period preceding infec-
tion with the ESBL producers. Only 7% had
chronic indwelling urinary catheters. Not surpris-
ingly, 82% initially were treated empirically with
antibiotics to which the strain was resistant. The
integration of these data with a hypothesis of a
common source outbreak is difﬁcult, unless it is
assumed that food sources led to faecal colonisa-
tion as an antecedent to UTI. New clinical infec-
tions in non-hospital residential healthcare
facilities led to employment in Shropshire of a
full-time nurse-educator to upgrade nursing
hygiene and practice, with particular attention to
catheter care, including unbroken drainage and
bag care, and ensuring that wash-bowls were not
shared. Nursing homes from which patients with
ESBL producers were admitted, or to which they
were discharged, were prioritised for inspection.
Antibiotic policy change
To reduce selection for these ESBL-producing
E. coli strains, changes were made to antibiotic
policy at the Shropshire hospitals. First, attempts
were made to reduce cephalosporin use. Use in
UTI was discouraged, and they were only advo-
cated in cases of the severest pneumonia, but not
in cases of chronic obstructive pulmonary disease.
Second, less successful attempts were made to
reduce quinolone use. Quinolones other than
ciproﬂoxacin and norﬂoxacin had never been
used in the hospitals for respiratory infection,
and an attempt was made to reduce the empirical
use of these agents, except in cases of neutropenia
and cirrhosis. Third, ertapenem, or occasionally
imipenem, was used empirically for suspected
Gram-negative sepsis of community origin, and
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for sepsis in all patients with a past history of
sepsis due to ESBL producers. Imipenem was
used in hospital-acquired Gram-negative sepsis
and as the initial empirical choice in cases of
ventilator-associated pneumonia. Cephalosporin
use was discontinued for prophylaxis and treat-
ment in gut surgery, and gentamicin (active
against the prevalent local (Group A) CTX-M-15-
producing E. coli strain) was used as appropriate,
in combination with benzylpenicillin and metro-
nidazole; imipenem or ertapenem was substituted
in patients with renal impairment. b-Lactam–
inhibitor combinations were neither reported nor
routinely encouraged, since most ESBL producers
were resistant to piperacillin–tazobactam. Co-
amoxiclav use was restricted to gynaecol-
ogy ⁄ obstetrical, ear, nose and throat and paediat-
ric infections, where ESBL producers remained
rare. The effects of these changes on antibiotic use
in the Royal Shrewsbury and Princess Royal
Hospital, Telford, in this period are shown in
Fig. 1.
From April 2004, changes were made to all
laboratory antibiotic reporting – including for phy-
sicians in primary care – to inﬂuence prescribing.
Quinolone reporting, hitherto unrestricted for
urinary infection, was restricted to Gram-negative
isolates resistant to amoxycillin and trimetho-
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Fig. 1. Selected antibiotic use at (a)
Shrewsbury hospital and (b) Telford
hospital.
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prim. Suppression of cephalosporin reporting
continued, whereas routine reporting of nitrofur-
antoin was introduced. However, it was difﬁcult
to ensure that junior doctors did not prescribe
nitrofurantoin for upper UTI, and treatment
failures were seen with nitrofurantoin-susceptible
organisms, consistent with a rate of asymptomatic
upper UTI of 15%. Recurrences and a modest 5%
increase in resistance were noted with nitrofur-
antoin during the study period. This agent is
completely absorbed and does not affect the gut
ﬂora. Occasional patients were treated on the
basis of combination disk tests with oral cefpo-
doxime in combination with amoxycillin–clavul-
anate, without adverse effects.
These antibiotic policy changes had no effect,
over 3 months, on the incidence of cases (Fig. 2).
Concentration of patients
We initially attempted to place patients known to
be infected or colonised with ESBL-producing
E. coli in single rooms, without apparent effect on
the incidence and spread to more than 50 wards
in two general and ﬁve smaller hospitals in
Shropshire. In September 2004, a cohort isolation
ward was introduced for all patients diagnosed
with, or known to have been infected or colonised
in the past with ESBL-producing E. coli. Contem-
poraneous control of the gentamicin-resistant
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ESBL-producing strain and decreased incidence
of gentamicin-susceptible ESBL-producing iso-
lates occurred (Fig. 2) in both hospitals and in
the primary-care populations.
Prolonged pre- and post-infection faecal
carriage.
It is uncertain whether faecal carriage is a risk-
factor for spread of infection, but this seems
plausible, given that some of the aged, dependent
individuals involved had problems with conti-
nence. Faeces were directly plated on cystine
lactose electrolyte depleted agar incorporating
ciproﬂoxacin (1 mg ⁄L), with a cefpodoxime disk
(10 lg) placed on the inoculum site. Resistant
isolates were conﬁrmed as ESBL-producing
E. coli using chromogenic urinary agar (BBL)
and IsoSensitest agar with cefpodoxime disks
with and without clavulanate.
This screening demonstrated the wide preva-
lence of ESBL-producing E. coli, the frequent
subsequent development of UTI, and differences
among producer strains. From September to
December 2003, the isolation rate was 2.3% for
475 faeces submitted from the community for the
investigation of bowel symptoms, as compared
with 5.2% for faeces from those in hospital. From
April 2003 to October 2005, rectal swabs or faeces
were sought on admission to hospital from all
patients who had been hospitalised or in a
residential healthcare environment in the preced-
ing 8 weeks and from all patients with a past
history of infection or colonisation with ESBL-
producing E. coli. In total, 2093 patients were
sampled, but compliance with the request was
poor, probably less than 25%. The patients were
then followed for clinical infection for a minimum
7-month period. Excluding those patients (4.2%
of the total) examined because they had a previ-
ous infection with ESBL-producing E. coli, the
asymptomatic carriage rate in this hospitalised
population was 2.7%. Gentamicin-resistant
(Groups B,D,E) and -susceptible (Group A)
strains behaved differently. The resistant strain
was found in 23% of clinical infections, but faecal
carriage prior to infection was seen in only two
patients (0.1% of total faeces), whereas 11 carriers
had no preceding or subsequent infection. The
ratio of carriage converting to infection was
therefore 13:2. The gentamicin-susceptible strain
accounted for 77% of clinical infections, and in
29 patients (1.39% of all faeces) faecal carriage
was detected prior to infection, whereas there
was no preceding or subsequent infection in
46 carriers. The ratio of carriage converting to
infection was therefore much higher for this
strain, at 75:29. This strain-dependent difference
in conversion to infection is statistically sig-
niﬁcant, but it is not clear whether it is associ-
ated with virulence factors. The occurrence of
aggregative adherence factors in the gentamicin-
susceptible strain A is noteworthy: diffuse
enteroadherence virulence factors of the dfr class
are known to be associated with recurrent urinary
infection and chronic renal infection, with the
yersiniabactin and aerobactin siderophore and
with clade B2 [25].
Clinical infections with ESBL-producing organ-
isms frequently recur, but the period for which
control measures should be applied to individuals
is unclear. The time elapsed between isolation of
ESBL-producing E. coli from faeces both before
and after ﬁrst infection with these strains is
shown in Fig. 3. Twenty per cent of the patients
were carriers, before and after infection, for more
than 1 year. Although 47% of patients presented
with community-diagnosed infection, only 20%
had no history of hospitalisation or contact with
residential homes. Therefore, as with Klebsiella
[26], acquisition of the organism can be distant
from the time when the patient develops, and is
diagnosed with, an infection. Finally, it should be
added that there are many uncertain UTIs diag-
nosed in the community that may follow organ-
ism addition to the faecal ﬂora in the hospital but,
alternatively, infection in the hospital may evolve
from colonisation acquired in the community.
Moreover, we lack comprehensive records of
catheterisation, so cannot assess whether cathe-
terisation was temporally associated with subse-
quent onset of infection.
Common sources of colonisation and infection:
the food chain
Consideration was given to the critical possibility
that ESBL-producing E. coli might be spreading
via the food supply – perhaps on a national rather
than a hospital scale, given the dispersed distri-
bution of the clonally related serotype O25 strain
in the UK. No clues were offered by dietary or
food origin history but, retrospectively, this is not
surprising, given the prolonged carriage periods
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prior to infection revealed in faecal colonisation
studies, and the admixture of hospital admissions
included in our initial study. There are now
several papers describing the presence of ESBL-
producing E. coli [27–31] in raw chicken and
meat, and also the presence of extra-intestinal
pathogenic quinolone-resistant E. coli [32–34],
including O25 strains. [34] There are, as yet, no
such reports for ready-to-eat food.
Although isolation of organisms in raw food,
which is to be cooked, would not normally be
regarded as a hazard for urinary E. coli infection,
it is regarded as a hazard for enteropathogens,
and the hazard might be real if raw meat contains
uropathogenic E. coli, and if the raw meat and
ready-to-eat foods are mixed in the catering
environment. Reassurance on the separation of
raw and cooked products as part of HACCP
control was obtained by inspection of our two
hospital kitchens. A 2006 survey of raw chicken
breast ﬁllets bought at local supermarkets did not
reveal E. coli with CTX-M-15 or any other CTX-M
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Fig. 3. Maximum intervals between detection of faecal carriage and urinary infection.
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type in British-produced chicken. However, other
CTX-M enzymes were present in raw chicken,
partially of overseas origin. Such local surveys do
not exclude the possibility that the problem with
E. coli with CTX-M-15 ESBL originated from
foodstuffs that were only brieﬂy available, with
subsequent transmission being human oro–faecal.
Control of mortality
An early issue with any new antibiotic resistance
is to control any increase in mortality due to
treatment failures. Any such increase may vary
with the site of infection and the choice of
empirical chemotherapy. Appropriate therapy,
once susceptibility data are available, is theoret-
ically easy to ensure. In Shropshire, 42 patients
with 47 bacteraemias due to ESBL-producing
E. coli, out of 630 infections, were seen in a 3-year
period. In 30 cases, the blood culture isolate was
the ﬁrst ESBL-producing isolate obtained from the
patient. Ertapenem and imipenem became the
empirical therapy of choice for bacteraemia seen
on medical units, limiting the use of non-active
therapy. Among the patients with bacteraemia
with ESBL producers who died, only 9 ⁄ 19 did so
within 15 days (45%). This compares with 189
deaths among 473 bacteraemias due to ESBL-
negative E. coli in 439 patients in the same time
period, in the same institution. Sixty-two (33%) of
these patients died within 15 days, suggesting
only a slight excess of associated mortality for the
ESBL producers.
Mortality in less severe infections, such as UTI,
has usually been reported to be low, but in this
ESBL outbreak was externally reported as high
[35]. Retrospectively matching controls for under-
lying condition is difﬁcult, but an unreported
local, retrospective, 28-day mortality cohort study
during 2002–2004 of 188 patients with ESBL-
producing E. coli was undertaken. This excluded
any patient who developed a bacteraemia, was
matched with controls by 10-year age bands, and
location in primary or secondary care. Matching
by morbidity and underlying condition was not
attempted. Four control groups were used:
(i) patients with trimethoprim-, amoxycillin-,
cephalosporin-, nitrofurantoin- and quinolone-
susceptible strains (n = 369); (ii) patients with
isolated trimethoprim resistance (n = 368); and
(iii ⁄ iv) two more poorly matched groups com-
prising all patients with quinolone-resistant
strains (n = 286). Mortality was signiﬁcantly
higher in cases with ESBL producers (20.7%)
than in all controls (p <0.05), with odds ratios of
approximately 2, except for the quinolone-resis-
tant controls. Adjustments for inpatient stay
eliminated any signiﬁcant difference between
the cases and those with strains resistant to
quinolones, but not producing ESBLs.
CONCLUSION
As a ﬁrst priority, antibiotic use must be made
appropriate and patient outcomes conﬁrmed to be
satisfactory, both initially and continuously, for
all infections. It is essential to integrate laborato-
ries for hospitals and their local communities and
to clearly delineate the epidemiology of resistant
strains and their acquisitions. In the case of ESBL-
producing E. coli, common sources in the food
chain should be investigated comprehensively,
systematically and, if necessary, on an interna-
tional scale. Their termination is probably criti-
cally important. Attention must be paid to the
risks in environments where the strain occurs,
aiming to decrease those practices that facilitate
infection or colonisation. This extends to spread
in residential non-hospital healthcare environ-
ments, which can be an important source of re-
introduction to hospitals. Hospital admissions
from potential sources in other healthcare envi-
ronments, therefore, should be screened and
computer alerts used to admit those previously
found positive for carriage, so that containment
isolation can be undertaken. The use of cohort
concentration to restrict the risk of cross-infection,
and to speed appropriate treatment and dis-
charge, should be considered, especially if there
are insufﬁcient single rooms. The extent and
duration of asymptomatic carriage and associated
risk of recurrence and spread will inﬂuence the
use of such accommodation.
The level at which control becomes impossible
is a value judgement, but rising incidence is
important, given the dearth of new oral agents for
the treatment of infection due to Gram-negative
bacteria.
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